Table 3.

Assessment of in vitro drug interactions against intracellular Leishmania amastigotes

Drug combination	Mean FICaS Mean $\sum \text{FICs}$a		Interaction type
	5ASKH	AG83	5ASKH	AG83
Suramin–paromomycin	0.34 ± .04	0.38 ± 0.07	Synergism	Synergism
Suramin–netilmicin	0.40 ± 0.06	0.41 ± 0.05	Synergism	Synergism
Curcumin–suramin	0.48 ± 0.08	1.18 ± 0.24	Synergism	Indifference
Curcumin–netilmicin	0.23 ± 0.15	0.35 ± 0.13	Synergism	Synergism
Curcumin–paromomycin	0.34 ± 0.15	0.61 ± 0.35	Synergism	Indifference
Curcumin–primaquine	0.63 ± 0.15	0.90 ± 0.38	Indifference	Indifference
Paromomycin–netilmicin	2.1 ± 0.12	1.8 ± 0.18	Indifference	Indifference
Primaquine–paromomycin	1.5 ± 0.2	1.1 ± 0.04	Indifference	Indifference

Results are given as mean ± SD of three independent experiments

^aMean of $\sum \text{FICs}$ were used to define the nature of the interactions between the drugs against intracellular L. major (5ASKH strain) and L. donovani (AG83 strain) amastigotes